Description

Medigene AG is a biotechnology firm dedicated to pioneering T cell immunotherapies aimed at combating cancer. Its primary therapeutic thrust involves personalized T cell-based treatments, specifically T cell receptor-modified T cells, which are currently undergoing clinical trials to address significant unmet medical needs. Beyond this core focus, Medigene also explores dendritic cell vaccines and specialized T cell monoclonal antibodies. Diverging from oncology, the company is additionally engaged in the development and commercialization of RhuDex for applications in hepatology and gastroenterology. Collaborations are key to Medigene's strategy; it maintains a strategic alliance with 2seventy bio, Inc. for advancing T cell receptor research. Furthermore, research cooperation agreements are in place with the Université de Montréal and Cytovant Sciences Co. Ltd. to discover and develop novel cancer antigens for immunotherapy. Established in 1994, the company's headquarters are located in Munich, Germany, with its operational footprint spanning Europe, the United States, Asia, and other international regions.